Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson
Nvidia is championing generative AI as a transformative technology in health care. The company suggests that its AI could help in drug discovery, diagnosis, and treatment planning, potentially ushering in a new era of personalized medicine and lower costs. Their AI approaches problems by generating hypotheses and learning from data, unlike traditional software that follows predefined rules. However, skeptics caution against over-hyping the technology, pointing to IBM's experience with Dr. Watson. IBM's AI was also marketed as a tool capable of revolutionizing health care—able to interpret medical information and support doctors in choosing treatments for cancer patients. Yet, despite the initial excitement, Watson fell short of expectations. It struggled to integrate into clinical workflows and faced criticism for its limited understanding of complex medical data. This serves as a reminder of the challenges AI faces in truly reshaping health care. The technology must prove its reliability, safely integrate with existing systems, and demonstrate clear benefits over current practices. Only time will tell if generative AI will meet these challenges and fulfill its potential in the health care industry, avoiding the pitfalls that limited its predecessors.
Comments